Johnson & Johnson (JNJ) last closed at $257.78, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for JNJ, covered for search and blurred for visitors.
Performance
1D-0.61%
5D+1.52%
1M-4.24%
3M-0.57%
6M+14.01%
1Y+33.07%
5Y+61.92%
Financials
Over the latest four reported periods ending September 27, 2026, Johnson & Johnson reported revenue of $99.33 billion.
The prior window totaled $92.15 billion, so the latest window is higher than that stretch.
Operating cash flow in the latest window was $26.16 billion.
Free cash flow in the latest window was $20.59 billion.
These amounts are taken from Johnson & Johnson's SEC filings and are a snapshot as of September 27, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.
A few ratios from those statements: Profitability: ROE 0.3% (17 of 100). Leverage: D/E 0.44× (82 of 100). Cash generation: FCF margin 20.7% (41 of 100). Net margin: 0.8% (2 of 100). Liquidity: Current 1.02× (51 of 100).
Finorify's notes from those filings, written August 27, 2026: Diversified Leadership Across Pharmaceuticals and MedTech. Johnson & Johnson operates two high-barrier, scaled segments—Innovative Medicine and MedTech. This dual-pillar business model provides revenue resilience, broad exposure across therapeutic areas (oncology, immunology, neuroscience) and surgical/interventional devices, and insulates total cash flows from downturns in any single product category. Extensive Global Distribution and Commercial Infrastructure. With established relationships spanning hospital networks, surgeons, health systems, and government payers worldwide, JNJ possesses an entrenched commercial scale and supply chain that new entrants cannot easily replicate, ensuring rapid commercialization and global reach for newly approved products. High-Yield R&D Pipeline and Strategic Capital Allocation. Supported by one of the strongest balance sheets in the healthcare industry, JNJ consistently reinvests substantial capital into internal R&D and targeted acquisitions/licensing, driving a steady cadence of next-generation therapies, proprietary medical devices, and protected intellectual property. Patent Expirations and Biosimilar Competition. A significant portion of Innovative Medicine revenue depends on high-margin blockbuster therapies. As core patents expire (such as for key immunology and oncology treatments), JNJ faces rapid revenue erosion from generic and biosimilar competition if replacement pipeline assets underperform. Significant Product Liability and Legacy Litigation Exposure. JNJ remains subject to large-scale, persistent product liability claims (including legacy talc litigation and medical device disputes), which introduce unpredictable multi-billion-dollar legal liabilities, settlement costs, and reputational risk. Government Pricing Controls and Reimbursement Headwinds. Evolving regulatory frameworks—such as Medicare drug price negotiation provisions under the U.S. Inflation Reduction Act and centralized price controls in international markets—place continuous downward pressure on reimbursement rates and drug pricing power.
Cash Flow
Margins
Valuation
P/E (TTM)
39.18
P/S (TTM)
6.25
EV/EBITDA
12.87
Insights
Advantage
Diversified Leadership Across Pharmaceuticals and MedTech
Johnson & Johnson operates two high-barrier, scaled segments—Innovative Medicine and MedTech. This dual-pillar business model provides revenue resilience, broad exposure across therapeutic areas (oncology, immunology, neuroscience) and surgical/interventional devices, and insulates total cash flows from downturns in any single product category.
Advantage
Extensive Global Distribution and Commercial Infrastructure
With established relationships spanning hospital networks, surgeons, health systems, and government payers worldwide, JNJ possesses an entrenched commercial scale and supply chain that new entrants cannot easily replicate, ensuring rapid commercialization and global reach for newly approved products.
Advantage
High-Yield R&D Pipeline and Strategic Capital Allocation
Supported by one of the strongest balance sheets in the healthcare industry, JNJ consistently reinvests substantial capital into internal R&D and targeted acquisitions/licensing, driving a steady cadence of next-generation therapies, proprietary medical devices, and protected intellectual property.
Risk
Patent Expirations and Biosimilar Competition
A significant portion of Innovative Medicine revenue depends on high-margin blockbuster therapies. As core patents expire (such as for key immunology and oncology treatments), JNJ faces rapid revenue erosion from generic and biosimilar competition if replacement pipeline assets underperform.
Risk
Significant Product Liability and Legacy Litigation Exposure
JNJ remains subject to large-scale, persistent product liability claims (including legacy talc litigation and medical device disputes), which introduce unpredictable multi-billion-dollar legal liabilities, settlement costs, and reputational risk.
Risk
Government Pricing Controls and Reimbursement Headwinds
Evolving regulatory frameworks—such as Medicare drug price negotiation provisions under the U.S. Inflation Reduction Act and centralized price controls in international markets—place continuous downward pressure on reimbursement rates and drug pricing power.
Read the live analysis in Finorify
Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.